EU/3/18/2011

Table of contents

About

On 16 April 2018, orphan designation (EU/3/18/2011) was granted by the European Commission to Ultragenyx Germany GmbH, Germany, for burosumab for the treatment of phosphaturic mesenchymal tumour.

Key facts

Active substance
Burosumab
Disease / condition
Treatment of phosphaturic mesenchymal tumour
Date of decision
16/04/2018
Outcome
Positive
Orphan decision number
EU/3/18/2011

Sponsor's contact details

Ultragenyx Germany GmbH
Stadtquartier Friedrichstr. 191
10117 Berlin
Germany
Tel. +49 30 20659217
E-mail: RSchulze@ultragenyx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating